Birmingham, AL46 Active Studies

Atopic Dermatitis Clinical Trials in Birmingham, AL

Find 46 actively recruiting atopic dermatitis clinical trials in Birmingham, AL. Connect with local research sites and explore new treatment options.

46
Active Trials
31
Sponsors
23,534
Enrolling

Recruiting Atopic Dermatitis Studies in Birmingham

RecruitingBirmingham, ALNCT02693535

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or ...

4,200 participants
American Society of Clinical Oncology
View Study Details
RecruitingBirmingham, ALNCT05882877

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD....

2,200 participants
Amgen
View Study Details
RecruitingBirmingham, ALNCT05492578

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. The purpose of this st...

1,551 participants
Sanofi
View Study Details
RecruitingBirmingham, ALNCT05889182

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how s...

1,328 participants
AbbVie
View Study Details
RecruitingBirmingham, ALNCT06468228

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under ar...

1,280 participants
AbbVie
View Study Details
RecruitingBirmingham, ALNCT06129864

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HN...

1,145 participants
AstraZeneca
View Study Details
RecruitingBirmingham, ALNCT05769777

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD). The purpose of this study is to characterize the long-term safety a...

901 participants
Sanofi
View Study Details
RecruitingBirmingham, ALNCT05538663

Intravesical BCG vs GEMDOCE in NMIBC

The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival...

870 participants
ECOG-ACRIN Cancer Research Group
View Study Details
RecruitingBirmingham, ALNCT06788990

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficeraf...

650 participants
Bicara Therapeutics
View Study Details
RecruitingBirmingham, ALNCT01810913

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage I...

613 participants
National Cancer Institute (NCI)
View Study Details
RecruitingBirmingham, ALNCT06855498

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib....

600 participants
Incyte Corporation
View Study Details
RecruitingBirmingham, ALNCT02339571

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melan...

600 participants
National Cancer Institute (NCI)
View Study Details
RecruitingBirmingham, ALNCT02138734

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC....

596 participants
ImmunityBio, Inc.
View Study Details
RecruitingBirmingham, ALNCT06840392

Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis sup...

555 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBirmingham, ALNCT06958211

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa....

450 participants
Incyte Corporation
View Study Details
RecruitingBirmingham, ALNCT05566795

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in ...

400 participants
Day One Biopharmaceuticals, Inc.
View Study Details
RecruitingBirmingham, ALNCT05559359

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermat...

360 participants
Eli Lilly and Company
View Study Details
RecruitingBirmingham, ALNCT04752722

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phase...

350 participants
enGene, Inc.
View Study Details
RecruitingBirmingham, ALNCT05995964

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash,...

340 participants
Pfizer
View Study Details
RecruitingBirmingham, ALNCT06241118

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on backgroun...

330 participants
Sanofi
View Study Details
RecruitingBirmingham, ALNCT07000084

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has...

330 participants
Alliance for Clinical Trials in Oncology
View Study Details
RecruitingBirmingham, ALNCT05316155

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose...

262 participants
Janssen Research & Development, LLC
View Study Details
RecruitingBirmingham, ALNCT06832618

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis....

240 participants
Incyte Corporation
View Study Details
RecruitingBirmingham, ALNCT06947993

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD)....

224 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBirmingham, ALNCT04166409

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated lo...

220 participants
National Cancer Institute (NCI)
View Study Details
RecruitingBirmingham, ALNCT06024499

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts....

210 participants
Shaperon
View Study Details
RecruitingBirmingham, ALNCT06635785

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors....

204 participants
OncoC4, Inc.
View Study Details
RecruitingBirmingham, ALNCT07006792

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Pa...

200 participants
Eli Lilly and Company
View Study Details
RecruitingBirmingham, ALNCT06311682

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat ...

195 participants
LEO Pharma
View Study Details
RecruitingBirmingham, ALNCT02734537

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. ...

189 participants
ECOG-ACRIN Cancer Research Group
View Study Details
RecruitingBirmingham, ALNCT04671667

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with...

188 participants
National Cancer Institute (NCI)
View Study Details
RecruitingBirmingham, ALNCT06818643

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumor...

180 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBirmingham, ALNCT03180268

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by sur...

163 participants
NRG Oncology
View Study Details
RecruitingBirmingham, ALNCT06603844

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and hav...

156 participants
Corbus Pharmaceuticals Inc.
View Study Details
RecruitingBirmingham, ALNCT05271409

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the doubl...

152 participants
Hoffmann-La Roche
View Study Details
RecruitingBirmingham, ALNCT06807268

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study...

150 participants
Pfizer
View Study Details
RecruitingBirmingham, ALNCT06712823

An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894)....

150 participants
Crinetics Pharmaceuticals Inc.
View Study Details
RecruitingBirmingham, ALNCT06956235

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesi...

147 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBirmingham, ALNCT06727552

A Study of Barzolvolimab in Patients With Atopic Dermatitis

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis...

120 participants
Celldex Therapeutics
View Study Details
RecruitingBirmingham, ALNCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adj...

100 participants
Reunion Neuroscience Inc
View Study Details
RecruitingBirmingham, ALNCT06998056

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema)....

100 participants
Arcutis Biotherapeutics, Inc.
View Study Details
RecruitingBirmingham, ALNCT07197034

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us ...

90 participants
Aardvark Therapeutics, Inc.
View Study Details
RecruitingBirmingham, ALNCT06828861

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The...

90 participants
Aardvark Therapeutics, Inc.
View Study Details
RecruitingBirmingham, ALNCT05694884

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermat...

75 participants
ASLAN Pharmaceuticals
View Study Details
RecruitingBirmingham, ALNCT02934568

Ribociclib (LEE011) Rollover Study for Continued Access

This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-spons...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBirmingham, ALNCT04929236

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients...

30 participants
Octapharma
View Study Details

About Atopic Dermatitis Clinical Trials in Birmingham

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 46 atopic dermatitis clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 23,534 participants. Research is being sponsored by American Society of Clinical Oncology, Amgen, Sanofi and 28 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Birmingham — FAQ

Are there atopic dermatitis clinical trials in Birmingham?

Yes, there are 46 atopic dermatitis clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 46 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated March 2, 2026 from ClinicalTrials.gov